Adult Blepharitis Questions & Answers

1. Gaddie IB, Donnenfeld ED, Karpecki P, Vollmer P, Berdy GJ, Peterson JD, et al. Lotilaner Ophthalmic Solution 0.25% for Demodex Blepharitis: Randomized, Vehicle-Controlled, Multicenter, Phase 3 Trial (Saturn-2). Ophthalmology. 2023 Jun 5. [QxMD MEDLINE Link]. [Full Text].

2. Chudzicka-Strugała I, Gołębiewska I, Brudecki G, Elamin W, Zwoździak B. Demodicosis in Different Age Groups and Alternative Treatment Options-A Review. J Clin Med. 2023 Feb 19. 12 (4):[QxMD MEDLINE Link]. [Full Text].

3. Lemp MA, Crews LA, Bron AJ, Foulks GN, Sullivan BD. Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. Cornea. 2012 May. 31 (5):472-8. [QxMD MEDLINE Link].

4. Onghanseng N, Ng SM, Halim MS, Nguyen QD. Oral antibiotics for chronic blepharitis. Cochrane Database Syst Rev. 2021 Jun 9. 6 (6):CD013697. [QxMD MEDLINE Link]. [Full Text].

5. Zhao L, Sun YJ, Pan ZQ. Topical Steroids and Antibiotics for Adult Blepharokeratoconjunctivitis (BKC): A Meta-Analysis of Randomized Clinical Trials. J Ophthalmol. 2021. 2021:3467620. [QxMD MEDLINE Link].

6. Pinckney J 2nd, Cole P, Vadapalli SP, Rosen T. Phthiriasis palpebrarum: a common culprit with uncommon presentation. Dermatol Online J. 2008 Apr 15. 14(4):7. [QxMD MEDLINE Link].

7. Divani S, Barpakis K, Kapsalas D. Chronic blepharitis caused by Demodex folliculorum mites. Cytopathology. 2009 Mar 7. [QxMD MEDLINE Link].

8. Dhingra KK, Saroha V, Gupta P, Khurana N. Demodex-associated dermatologic conditions - A coincidence or an etiological correlate. Review with a report of a rare case of sebaceous adenoma. Pathol Res Pract. 2009 Jan 22. [QxMD MEDLINE Link].

9. Jackson WB. Blepharitis: current strategies for diagnosis and management. Can J Ophthalmol. 2008 Apr. 43(2):170-9. [QxMD MEDLINE Link].

10. Yeu E, Wirta DL, Karpecki P, Baba SN, Holdbrook M, Saturn I Study Group. Lotilaner Ophthalmic Solution, 0.25%, for the Treatment of Demodex Blepharitis: Results of a Prospective, Randomized, Vehicle-Controlled, Double-Masked, Pivotal Trial (Saturn-1). Cornea. 2023 Apr 1. 42 (4):435-443. [QxMD MEDLINE Link]. [Full Text].

11. Luchs J. Efficacy of topical azithromycin ophthalmic solution 1% in the treatment of posterior blepharitis. Adv Ther. 2008 Sep. 25(9):858-70. [QxMD MEDLINE Link].

12. Holzchuh FG, Hida RY, Moscovici BK, Villa Albers MB, Santo RM, Kara-José N, et al. Clinical Treatment of Ocular Demodex folliculorum by Systemic Ivermectin. Am J Ophthalmol. 2011 Jun. 151(6):1030-1034.e1. [QxMD MEDLINE Link].

13. Arky R. Acromycin V tetracycline HCl. Physicians' Desk Reference. 53rd ed. 1999. 1514-1515. [Full Text].

14. Cohen EJ. Cornea and external disease in the new millennium. Arch Ophthalmol. 2000 Jul. 118(7):979-81. [QxMD MEDLINE Link].

15. Diaz-Valle D, Benitez del Castillo JM, Fernandez Acenero MJ. Bilateral lid margin ulcers as the initial manifestation of Crohn disease. Am J Ophthalmol. 2004 Aug. 138(2):292-4. [QxMD MEDLINE Link].

16. Fraunfelder FT, Roy FH, Steinemann TL. Current Ocular Therapy. 5th ed. 2000. 72, 374, 378, 450.

17. Galea M, Sharma R, Srinivasan S, Roberts F. Demodex blepharitis mimicking eyelid sebaceous gland carcinoma. Clin Experiment Ophthalmol. 2013 Apr 9. [QxMD MEDLINE Link].

18. Held KS. Blepharitis. Decision Making in Ophthalmology. 2nd ed. 2000. 50-51.

19. Kanski JJ. Marginal blepharitis. Clinical Ophthalmology. 1984. 1.2-1.4.

20. Roy FH. Ocular Differential Diagnosis. 7th ed. 2002.

21. Sullivan JH. Lids and lacrimal apparatus. General Ophthalmology. 14th ed. 1995. 78-81.

22. Weisbecker CA, Fraunfelder FT, Rhee D. Physicians' Desk Reference for Ophthalmology. 28th ed. 2000.

23. Yanoff M, Fine BS. Inflammation. Ocular Pathology. 4th ed. 1996. 166-168.

24. Tighe S, Gao YY, Tseng SC. Terpinen-4-ol is the Most Active Ingredient of Tea Tree Oil to Kill Demodex Mites. Transl Vis Sci Technol. 2013 Nov. 2 (7):2. [QxMD MEDLINE Link].

25. Hart PH, Brand C, Carson CF, Riley TV, Prager RH, Finlay-Jones JJ. Terpinen-4-ol, the main component of the essential oil of Melaleuca alternifolia (tea tree oil), suppresses inflammatory mediator production by activated human monocytes. Inflamm Res. 2000 Nov. 49 (11):619-26. [QxMD MEDLINE Link].

26. Carson CF, Hammer KA, Riley TV. Melaleuca alternifolia (Tea Tree) oil: a review of antimicrobial and other medicinal properties. Clin Microbiol Rev. 2006 Jan. 19 (1):50-62. [QxMD MEDLINE Link].

R Scott Lowery, MD Associate Professor of Ophthalmology, Department of Pediatric Ophthalmology and Strabismus, University of Arkansas for Medical Sciences College of Medicine, Arkansas Children's Hospital

R Scott Lowery, MD is a member of the following medical societies: American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus, Arkansas Medical Society

Disclosure: Nothing to disclose.

Simon K Law, MD, PharmD Clinical Professor of Health Sciences, Department of Ophthalmology, Jules Stein Eye Institute, University of California, Los Angeles, David Geffen School of Medicine

Simon K Law, MD, PharmD is a member of the following medical societies: American Academy of Ophthalmology, Association for Research in Vision and Ophthalmology, American Glaucoma Society

Disclosure: Nothing to disclose.

Christopher J Rapuano, MD Professor, Department of Ophthalmology, Sidney Kimmel Medical College of Thomas Jefferson University; Director of the Cornea Service, Wills Eye Hospital

Christopher J Rapuano, MD is a member of the following medical societies: American Academy of Ophthalmology, American Ophthalmological Society, American Society of Cataract and Refractive Surgery, Contact Lens Association of Ophthalmologists, Cornea Society, Eye Bank Association of America, International Society of Refractive Surgery

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: AAO; OMIC; American Society of Ophthalmic Trauma (ASOT); Avellino, Baxis; Bio-Tissue; Celularity; Dompe; Emmecell; Glaukos; Kala; Oyster Point; Sun Ophthalmics; Tarsus; TearLab<br/>Serve(d) as a speaker or a member of a speakers bureau for: Glaukos; Dompe; Bio-Tissue<br/>Received research grant from: Glaukos<br/>Received income in an amount equal to or greater than $250 from: AAO; OMIC; Baxis; Bio-Tissue; Cellularity; Dompe; Glaukos; Kala; Sun Ophthalmics; TearLab<br/>stock options for: RPS, Fount Bio.

Andrew A Dahl, MD, FACS Assistant Professor of Surgery (Ophthalmology), New York College of Medicine (NYCOM); Director of Residency Ophthalmology Training, The Institute for Family Health and Mid-Hudson Family Practice Residency Program; Staff Ophthalmologist, Telluride Medical Center

Andrew A Dahl, MD, FACS is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, American Intraocular Lens Society, American Medical Association, American Society of Cataract and Refractive Surgery, Contact Lens Association of Ophthalmologists, Medical Society of the State of New York, New York State Ophthalmological Society, Outpatient Ophthalmic Surgery Society

Disclosure: Nothing to disclose.

Fernando H Murillo-Lopez, MD Senior Surgeon, Unidad Privada de Oftalmologia CEMES

Fernando H Murillo-Lopez, MD is a member of the following medical societies: American Academy of Ophthalmology

Disclosure: Nothing to disclose.

• Print this section
• Print the entire contents of
• Print the entire contents of article